Ilian Tchakov

515 total citations
13 papers, 216 citations indexed

About

Ilian Tchakov is a scholar working on Oncology, Reproductive Medicine and Molecular Biology. According to data from OpenAlex, Ilian Tchakov has authored 13 papers receiving a total of 216 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 4 papers in Reproductive Medicine and 2 papers in Molecular Biology. Recurrent topics in Ilian Tchakov's work include PARP inhibition in cancer therapy (7 papers), Ovarian cancer diagnosis and treatment (4 papers) and Head and Neck Cancer Studies (2 papers). Ilian Tchakov is often cited by papers focused on PARP inhibition in cancer therapy (7 papers), Ovarian cancer diagnosis and treatment (4 papers) and Head and Neck Cancer Studies (2 papers). Ilian Tchakov collaborates with scholars based in United Kingdom, United States and Netherlands. Ilian Tchakov's co-authors include Ruud van der Noll, Peter Vuylsteke, Helen Mackay, Serena Marchetti, Geoffrey I. Shapiro, Martijn P. Lolkema, Jacqui Rowbottom, Min Ren, David Cibula and Chean Eng Ooi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Radiotherapy and Oncology.

In The Last Decade

Ilian Tchakov

13 papers receiving 213 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ilian Tchakov United Kingdom	8	149	73	63	50	39	13	216
Eva Guerra Spain	8	88 0.6×	29 0.4×	70 1.1×	29 0.6×	13 0.3×	22	150
Daliah Tsoref Israel	6	59 0.4×	66 0.9×	52 0.8×	16 0.3×	41 1.1×	15	166
Anna Pawłowska Poland	10	126 0.8×	60 0.8×	85 1.3×	117 2.3×	8 0.2×	21	246
Saira Khalique United Kingdom	7	72 0.5×	107 1.5×	96 1.5×	23 0.5×	16 0.4×	11	193
Mansoor R. Mirza Denmark	5	143 1.0×	34 0.5×	79 1.3×	18 0.4×	19 0.5×	10	168
Simon P. Watkins United States	7	147 1.0×	60 0.8×	22 0.3×	32 0.6×	9 0.2×	17	166
K Gugała Poland	5	116 0.8×	112 1.5×	19 0.3×	9 0.2×	65 1.7×	9	201
Eugenia Ortega Spain	6	44 0.3×	42 0.6×	20 0.3×	5 0.1×	7 0.2×	9	114
Stephen J. Luen Australia	3	108 0.7×	61 0.8×	11 0.2×	43 0.9×	14 0.4×	7	143
Le Tang China	7	66 0.4×	186 2.5×	6 0.1×	21 0.4×	7 0.2×	14	285

Countries citing papers authored by Ilian Tchakov

Since Specialization

Citations

This map shows the geographic impact of Ilian Tchakov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ilian Tchakov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ilian Tchakov more than expected).

Fields of papers citing papers by Ilian Tchakov

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ilian Tchakov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ilian Tchakov. The network helps show where Ilian Tchakov may publish in the future.

Co-authorship network of co-authors of Ilian Tchakov

This figure shows the co-authorship network connecting the top 25 collaborators of Ilian Tchakov. A scholar is included among the top collaborators of Ilian Tchakov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ilian Tchakov. Ilian Tchakov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Ho, Alan L., Lisle Nabell, Prakash Neupane, et al.. (2024). HB-200 arenavirus-based immunotherapy plus pembrolizumab as first-line treatment of patients with recurrent/metastatic HPV16-positive head and neck cancer: Updated results.. Journal of Clinical Oncology. 42(16_suppl). 6005–6005. 5 indexed citations

Plummer, Ruth, Mikael H. Sodergren, David J. Pinato, et al.. (2021). 515 A phase 1 study of myeloid modulating agent MTL-CEBPA in combination with pembrolizumab in adult patients with advanced solid tumours. SHILAP Revista de lepidopterología. A545–A545. 1 indexed citations

Hong, David S., Aparna R. Parikh, Geoffrey I. Shapiro, et al.. (2020). First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE₂-receptor E-type 4 (EP4), in patients with advanced cancers. Journal for ImmunoTherapy of Cancer. 8(1). e000222–e000222. 54 indexed citations

Noll, Ruud van der, Agnes Jager, Joo Ern Ang, et al.. (2019). Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). Investigational New Drugs. 38(4). 1096–1107. 10 indexed citations

Noll, Ruud van der, Agnes Jager, Joo Ern Ang, et al.. (2019). Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1). Investigational New Drugs. 38(4). 1117–1128. 11 indexed citations

Hong, David S., Aparna R. Parikh, Geoffrey I. Shapiro, et al.. (2018). Phase I study of E7046, a novel PGE₂ receptor type 4 inhibitor, in patients with advanced solid tumors: Clinical results and effects on myeloid- and T-lymphoid cell-mediated immunosuppression.. Journal of Clinical Oncology. 36(5_suppl). 49–49. 2 indexed citations

Tyczynski, Jerzy E., et al.. (2015). Real-world treatment patterns for platinum-sensitive recurrent serous ovarian cancer: Findings from a multinational medical record review.. Journal of Clinical Oncology. 33(15_suppl). e16548–e16548. 1 indexed citations

Noll, Ruud van der, Joo Ern Ang, Agnes Jager, et al.. (2013). Phase I study of olaparib in combination with carboplatin and/or paclitaxel in patients with advanced solid tumors.. Journal of Clinical Oncology. 31(15_suppl). 2579–2579. 26 indexed citations

Oza, Amit M., David Cibula, Ana Oaknin, et al.. (2012). Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study.. Journal of Clinical Oncology. 30(15_suppl). 5001–5001. 47 indexed citations

10.

Gupta, Avinash, Víctor Moreno, Emma Dean, et al.. (2012). Phase I study to determine the bioavailability and tolerability of a tablet formulation of the PARP inhibitor olaparib in patients with advanced solid tumors: Dose-escalation phase.. Journal of Clinical Oncology. 30(15_suppl). 3051–3051. 9 indexed citations

11.

Bénard, François, Don Wilson, Montgomery Martin, et al.. (2012). FDG PET early metabolic response to the PARP inhibitor olaparib (AZD2281) in BRCA-deficient or recurrent high-grade ovarian carcinoma and BRCA-deficient or triple-negative breast cancer. 53. 63–63. 1 indexed citations

12.

Molife, L Rhoda, Joaquı́n Mateo, Matthew Krebs, et al.. (2012). Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations.. Journal of Clinical Oncology. 30(15_suppl). 3048–3048. 14 indexed citations

13.

Grégoire, Vincent, Marc Hamoir, Changhu Chen, et al.. (2011). Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: A phase II, randomized, double-blind, placebo-controlled study. Radiotherapy and Oncology. 100(1). 62–69. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact